



KU LEUVEN


Variant prioritization by genomic data fusion

Yves Moreau


University of Leuven, Belgium



Disease gene discovery in rare congenital disorders




Patients with congenital & acquired disorders





CGH microarrays
NGS sequencing



Statistical analysis



Location of chromosomal imbalances




- Map chromosomal abnormalities
- Improved diagnosis

- Discover new disease causing genes and explain their function

Prioritized candidate genes

Rank	En	Ex	Ip	Ke	GO	Te	Avg	Pval
1	TTR	66PC	PAH	66PC	IGF1	TTR		TTR
2	IGF1	TTR	IGF1	PAH	PAH	IGF1		PAH
3	CRP	ALB	TTR	RERE	66PC	CRP		66PC
4	HOXB6	HABP2	ALB	ERCC3	TTR	HOXB6		IGF1
5	ALB	PAH	HDC	ERCC3		ALB		ALB

Validation




Genetic diagnosis

- Main medical goals
 - End diagnostic odyssey
 - Estimate risk for next pregnancy
 - Predict disease progression, life expectancy, etc.
- Patient - deletion $\text{del}(22)(q12.2)$
 - Pulmonary valve stenosis
 - Cleft uvula
 - Mild dysmorphism
 - Mild learning difficulties
 - High myopia



Deletion del(22)(q12.2)



■ Deletion on Chromosome 22

- ~0.8Mb




■ Deletion contains NF2


- NF2 ↔ acoustic neurinomas

- Benign tumor, BUT

- Hard to diagnose

- Severe complications






Exome sequencing



- Clinical sequencing of whole genomes is around the corner
 - But data will be hard to interpret
- Exome sequencing
 - Routine clinical use has started
 - More conserved, fewer mutations, easier to interpret
- Some mutations are easy to interpret, but in most cases it will still be hard to identify which mutation causes disease
 - Can variants be prioritized?
 - Existing tools for variant deleteriousness prediction (SIFT, Polyphen, MutationTaster etc.) fall short

Exome sequencing and gene prioritization




Erlich, Y. et al. Exome sequencing and disease-network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis. *Genome Res.* 21, 658–664 (2011).

Data fusion




Prioritization by example

- Known/training genes
 - Type 2 diabetes: 21 known genes in OMIM, 118 known genes in GAD
 - Manually curated gene set from Elbers et al., 2007
 - ACDC, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, LEP, LEPR, NR3C1, UCP1, UCP2, UCP3, PPARG, KCNJ11, TCF7L2
- Candidate/test genes
 - Prioritizations of a known region (from Elbers et al., 2007)
 - 12q24: 327 candidates



Region 12q24: 327 candidates





Responsible for MODY, an uncommon monogenetic form of early onset T2D.

NCOR2 has an important role in the adipocyte by inhibiting adipocyte differentiation via repression of PPAR-g activity.


Key component in the reverse cholesterol transport pathway. Genetically associated with differences in insulin sensitivity in healthy subjects

Profiling known genes (Gene Ontology)




- A term is over-represented if its frequency inside the training set is significantly larger than its frequency over the genome
 - E.g., Gene Ontology, Interpro, KEGG

Scoring candidates




Annotations

	p-value
epith. dev.	1.1e-06
tissue mfg	1.9e-05
...	...
tube clzr	0.00457



	epith. dev.	tissue mfg	tube clzr
OTX2	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
TP53	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>




	p-value
OTX2	0.0005
...	...
TP53	1.0

Scoring derived from Fisher's omnibus statistic

$$S = -2 \sum_i \log p_i$$

Data fusion with order statistics



Endeavour

Aerts et al. *Nature Biotech.* 2006
www.esat.kuleuven.be/endeavour

Endeavour

File Edit Tools Help

Model

livergenes_model.bin lps_model.bin
prox1_model.bin ccnb2_coreg_model.bin
livergenes_model.bin

- Model
 - biovec.EnsemblEstModel
 - biovec.ExpressionModel_atlas
 - biovec.lprModel
 - biovec.KeggModel
 - biovec.GOModel
 - biovec.TextModel

Data

Training Set Test Sets Results SprintPlot

Rank	En	Ex	lp	Ke	GO	Te	Avg	Pval
1	TTR	G6PC	PAH	G6PC	IGF1	TTR		TTR
2	IGF1	TTR	IGF1	PAH	PAH	IGF1		PAH
3	CRP	ALB	TTR	RERE	G6PC	CRP		G6PC
4	HOXB6	HABP2	ALB	ERCC3	TTR	HOXB6		IGF1
5	ALB	PAH	HDC	ERCC3		ALB		ALB
6	NR4A2	IF	TLL2	ANKRD3		HMG2		CRP
7	PAH		C1QR1	ARAF1	HDC	NR4A2		HABP2
8	HOXA11	IGF1	G6PC	PKD2	F13A1	PAH		IF
9	NFYA	CRP	HABP2	MTMR1	KCNN3	HOXA11	C13orf7	FST
10	C9	ARAF1	IF	HDC	CLIC1	NFYA	TTR	ARAF1
11	PKD2	GPR6	C9	ASPA	TM4SF13	C9	IGF1	HMG2
12	BPAG1	GRIN2A	EPA7		FST	FOXC2	PAH	C9
13	FOXA2	PCBP2	EPA7	DUSP3		PKD2	G6PC	PCBP2
14	TGFB3	TGFBRA	HHIP	CDK9	IF	BPAG1	ALB	HOXB6
15	G6PC	FST	PIK4CB	TGFB3	CRH	FOXA2		RERE
16	GABPA	TLL2	ERCC3	CKMT1	PLUNC	TGFB3	HMG2	HOXA11
17	PCBP2	DUSP3	ERCC3	RPL34	NR3C2	G6PC	CRP	CLIC1
18	F13A1	STX8	MAGED2	FLOD2	STX8	GABPA		ERCC3
19	MEIS1	FOXC2	ZNF207	CKMT1	FLOD2	PCBP2	FST	ERCC3
20								


- Multiple species:
 - Human, mouse, rat, fly, worm
- Integration across species will soon be supported

Add Remove Score Refresh Save figure

Status


Saved data table to file lps_test.bin
Scoring entities in test set...
Scoring of biovec.ExpressionModel_atlas successful.
Scoring of biovec.EnsemblEstModel successful.
Scoring of biovec.KeggModel successful.
Scoring of biovec.lprModel successful.
Scoring of biovec.GOModel successful.
Scoring of biovec.TextModel successful.
Scoring Finished successfully.
Saved data table to file export

<http://www.esat.kuleuven.ac.be/endeavour>





Prioritization for a monogenic disorder



A novel locus for congenital heart defect on chromosome 6q24-25



Translocation t(2;6)(q21;q25)





Zebrafish morpholino knock-down



Mutation sequencing


- Sequencing of TAB2 in 270 CHD patients revealed 2 missense mutations





Kernel methods for genomic data fusion

Kernel-based genomic data fusion



Kernel matrix



~ nonlinear extension of covariance/correlation matrix

Instead of using original data directly, use kernel matrix only
(Think of hierarchical clustering.)



Advantage 1: kernel matrices form a single type of object, regardless of the heterogeneity of the original data types

Advantage 2: all machine learning methods can be applied to kernels (classification, clustering, prioritization, ranking, etc.)


Kernel data fusion (a.k.a. MKL)



Prioritization by novelty detection



One-class support vector machine



$$\boxed{\text{P:}} \min_{\vec{w}, \xi, \rho} \frac{1}{2} \vec{w}^T \vec{w} - \frac{1}{\nu l} \sum_{k=1}^l \xi_k - \rho$$

$$\text{s.t. } \vec{w}^T \phi(\vec{x}_k) \geq \rho - \xi_k, \quad k = 1, \dots, N$$

$$\xi_k \geq 0, \quad k = 1, \dots, N.$$

\vec{w} : the norm vector of the separating hyperplane

\vec{x}_k : the training samples

ν : a regularization term penalizing the outliers in the training samples

$\phi(\cdot)$: the feature map

ρ : the bias term

ξ_k : the slack variables

N : the number of training samples

$$\boxed{\text{D:}} \min_{\vec{\alpha}} \vec{\alpha}^T K \vec{\alpha}$$



$$\text{s.t. } 0 \leq \alpha_k \leq \frac{1}{\nu N}, \quad k = 1, \dots, N$$

$$\sum_{k=1}^N \alpha_k = 1,$$

α_k : the dual variables

K : the kernel matrix

Kernel fusion for novelty detection



Kernel fusion in one-class SVM

■ L_∞ -norm kernel fusion (De Bie et al., 2007)

$$\begin{aligned} \min_{\vec{\alpha}} \quad & t \\ \text{s.t.} \quad & t \geq \vec{\alpha}^T K_j \vec{\alpha}, \quad j = 1, \dots, p \\ & 0 \leq \alpha_k \leq \frac{1}{\nu N}, \quad k = 1, \dots, N \\ & \sum_{k=1}^N \alpha_k = 1, \end{aligned}$$


p : the number of kernel matrices

K_j : the j -th kernel matrix

■ L_2 -norm kernel fusion (Yu et al., 2009)

$$\begin{aligned} \min_{\vec{\alpha}} \quad & t \\ \text{s.t.} \quad & t \geq \|s_j\|_2, \quad j = 1, \dots, p \\ & s_j \geq \vec{\alpha}^T K_j \vec{\alpha}, \quad j = 1, \dots, p \\ & 0 \leq \alpha_k \leq \frac{1}{\nu N}, \quad k = 1, \dots, N \\ & \sum_{k=1}^N \alpha_k = 1. \end{aligned}$$

s_j : dummy variables



L_2 vs. L_∞ kernel fusion







Table 1: AUC values of LOO performance evaluated from 20 random repetitions. The paired Spearman correlation scores indicate the similarities of rankings obtained by different approaches compared with the target rankings (denoted as -).


	AUC	corr	corr	corr	corr
L_∞	0.9045(0.0043)	-	0.94	0.66	0.82
$L_\infty(0.5)$	0.9176(0.0040)	0.94	-	0.82	0.92
L_1	0.9103(0.0035)	0.66	0.82	-	0.90
L_2	0.9219(0.0034)	0.82	0.92	0.90	-






A framework for kernel data fusion

Kernel data fusion






ETkL: Extract, Transform, Kernelize, Learn

- Systematic multi-tier framework for data integration
 - Resembles multi-tier architecture of complex IT systems and Extract-Transform-Load methodology of data warehousing
 1. Database / web service sources
 2. Data reconciliation, cleaning, and warehousing, etc.
 3. Scaling, normalization, feature selection, etc.
 4. Computation and storage of kernels
 5. Learning
 - May require feedback loops (e.g., feature selection)
- Scale up to large, heterogeneous databases
- 20,000 x 20,000 kernel matrices are ugly animals

Handling large kernel matrices


- One way to handle large kernel matrices is via low-rank approximations
 - Store $r \times n$ instead of $n \times n$
- Cholesky decomposition
 - K symmetric positive definite


$$\exists C (\text{lower triangular \& unique}) : K = CC'$$



Incomplete Cholesky decomposition


- Incomplete Cholesky
 - K symmetric positive semidefinite
 - Limit to rank $r \leq \text{rank}(K)$
 - Add pivoting to capture more informative rows/columns first
 - Limit information loss to e.g. 5%





The No-Voodoo principle

- Given a data matrix D for a learning problem, the no voodoo principle states that, in the absence of prior knowledge or arbitrary assumptions, no information can be extracted about the problem except the information provided by the data matrix
 - In particular, no information can be created that wasn't initially present in the data
 - No amount of bagging, random projection, nonlinear high-dimensional feature map, etc. can extract information that was not present in the data (except through the implicit or explicit injection of constraints into the problem)
 - If two frameworks represent data in ways that are related in a one-to-one fashion, there is nothing that prevents the development of methods with identical accuracy (e.g., random projections vs. spectral methods)
 - If one method outperforms another on a given problem (remember the no free lunch theorem), it is because the methods are more or less efficient (in particular, in terms of generalization performance vs. retrospective accuracy) at capturing the available information or because the methods incorporate explicit or implicit constraints that are more or less relevant to the given learning task




eXstasy

Variant Prioritization


Challenges

- About 2,000 rare coding variants per patient
- About 5 *de novo* coding variants per patient
- Tractable by filtering
 - Loss-of-function (truncating, splice site) mutations
 - Two patients with *de novo* variants in same gene
 - Recessive mutations in inbred families
 - Multiple patients with rare variants in the same gene (association)
- Challenging
 - What about locus heterogeneity?
 - What about compound heterozygotes?
 - What about oligogenic disorders?
 - ➔ Need to prioritize variants




Variant prioritization


- Variant and basepair level
 - *Structural change*: change from one nucleotide to the another will change the amino-acid encoded at that position, which will change the structure of the protein and thus its function
 - *Association*: variant is present more often in patients than controls
 - *Conservation*: position at which the variant is found is highly conserved across species and evolution is apparently reluctant to see this position changed
- Gene level
 - *Haploinsufficiency*: gene in which the variant is found is putatively haploinsufficient
 - *Gene prioritization*: gene in which the variant is found is known to be involved or is putatively involved in the phenotype of interest
- Locus level
 - *Locus mapping*: region of the genome in which variant is found is associated (CNV, association, linkage) with phenotype of interest



Variant prioritization




Locus (Mb)



Genome-wide association studies

Copy number variation

Gene (kb)



Haploinsufficiency

Gene prioritization

Position or variant (bp)







Variant association

Conservation


Structural effects

Variant prioritization







homes.esat.kuleuven.be/~bioiuser/eXtasy/





Data sets

- HGMD: 24,454 variants in 1,142 HPO terms
 - HGMD terms mapped to HPO
 - At least three genes for training of Endeavour
- Control sets (sampled 500/phenotype):
 - Polymorphisms: MAF > 1%, 1000G, 43,724 variants
 - Rare
 - MAF < 1%, 1000G, 43,724 variants
 - In-house, > 20X coverage, 257, 556 variants
- Scores from different sources mapped directly from highest to lowest level
- Existing method perform poorly on rare *a priori* benign variants vs. polymorphisms



Polyphen2




SIFT





MutationTaster








Where is the problem?


- Previous methods trained to distinguish disease-causing variants from common SNPs, not rare variants
- “Deleterious” variant = variant that affects gene function
 - Deleterious variants may not be disease causing
 - “Mildly deleterious” – Kryukov et al. (2007)
 - “Accelerated population growth and weak purifying selection” – Tennessen et al. (2012)
- Bad training sets?
- What if they are deleterious but not specific for our desired phenotype?








TRAINING DATA



ANNOTATION



INPUT




TRAIN CLASSIFIER


OUTPUT




Random forests




- Stable
- Fast
- Semi-interpretable






Rare variants

A




B




Polymorphisms


C




D




Temporal stratification






A



B








What's the catch?

- Data sets are biased
 - Benchmark on known mutations
 - Retrospective benchmarks are overoptimistic!
- High proportion of negative variants
 - Despite good discrimination, still lots of false positives



Run eXtasy online:



Email:

HPO term:


Micrognathia

VCF file: miller.vcf

Example Data: [miller.vcf](#), [schinzel_giedion.vcf](#)

We provide two example vcf files which were generated by adding published disease causing variants for Miller syndrome (causative gene: DHODH, [Ng et al., 2010, Nature Genetics](#)) or Schinzel-Giedion syndrome (causative gene: SETBP1, [Hoischen et al., 2010, Nature Genetics](#)) to a publicly available VCF file of the exome of a healthy individual (obtained from [here](#)). These files can be prioritized against any of the phenotype terms which characterize the syndromes. For Schinzel-Giedion this could for example be *HP:0009924 (Hypoplasia/aplasia involving the nose)* or for Miller syndrome this could be *HP:0000347 (Micrognathia)*.

`homes.esat.kuleuven.be/~bioiuser/eXtasy/`




Conclusions and perspectives

- Genomic data fusion for disease gene prioritization
- Kernel methods for genomic data fusion
- Extract, Transform, kernelize & Learn
- Phenotype information improves variant prioritization
- Importance of reference data
 - Common SNPs
 - Rare *a priori* benign variants
 - *Common and rare variants from local population*
- Scoring for multiple phenotypes
- Further integration with locus info (GWAS, CNV)
- Further integration with variant association scoring
- Scoring other mutations (synonymous, indels, noncoding)

`homes.esat.kuleuven.be/~bioiuser/eXtasy/`



KU LEUVEN




Leo Tranchevent



Alejandro Sifrim



Dusan Popovic



**In collaboration with
Center for Human Genetics
University of Leuven
Joris Vermeesch**